On September 9, 2021, Agilent successfully delivered the first batch of SureSelect targeted capture probe products produced in China at its Hangzhou production base.

China has worked together with other countries in the world to overcome difficulties and contribute wisdom and strength to the global epidemic.

The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of MAs and collaborations, and rising focus on next-generation product